SecBot SecBot
8-K ·Filed Oct 26, 2026

APVO

Aptevo Therapeutics Inc.
NEUTRAL
Impact 4/10
Processed55m ago SEC0001193125-26-431079
8-K context-dependent: Items 8.01

Price Chart

Loading chart...

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-431079
Document: apvo-ex99_1.htm0001193125-26-431079
Document: 0001193125-26-431079-index-headers.html0001193125-26-431079
Document: 0001193125-26-431079-index.html0001193125-26-431079
Document: 0001193125-26-431079.txt0001193125-26-431079
11 reports for APVO
Performance horizon
50% Hit rate @ T+5 2 of 4 directional calls Went positive at some point 3 of 4 best @ T+60▲ +13.57%Mar 11, 2026
Filters
Rows
Reports for APVO — sortable, filterable
TypeNow
Oct 26, 2026
today
8-K
NEUTRAL ★ 4/10
$1.73awaiting T+5—$1.61 (−7.03%)
Oct 23, 2026
2d ago
8-K
NEUTRAL ★ 2/10
$1.61awaiting T+5—$1.61 (+0.00%)
Oct 14, 2026
12d ago
8-K
NEUTRAL ★ 3/10
$1.73 $1.60▼ −7.51%▼ −7.97%$1.61 (−6.94%)
Sep 24, 2026
4w ago
8-K
NEUTRAL ★ 3/10
$1.83 $1.76▼ −3.83%▼ −3.41%$1.61 (−12.02%)
Sep 3, 2026
7w ago
424B4 / 8-K
MIXED ★ 6/10
$1.71 $1.82▲ +6.43%▲ +7.58%$1.61 (−5.85%)
Sep 3, 2026
7w ago
EFFECT
BEARISH ★ 6/10
$1.71 $1.82▼ −6.43%▼ −7.58%$1.61 (+5.85%)
Aug 14, 2026
10w ago
8-K
MIXED ★ 5/10
$2.94 $2.68▼ −8.84%▼ −7.48%$1.61 (−45.24%)
Jul 27, 2026
12w ago
8-K
NEUTRAL ★ 4/10
$4.21 $3.95▼ −6.18%▼ −8.44%$1.61 (−61.76%)
Jun 30, 2026
16w ago
8-K
BULLISH ★ 5/10
$4.45 $4.51▲ +1.35%▲ +1.09%$1.61 (−63.82%)
May 6, 2026
24w ago
8-K
BULLISH ★ 6/10
$4.86 $4.76▼ −2.06%▼ −3.56%$1.61 (−66.87%)
Showing 10 of 11

US Market Status

Market Closed — Opens in 20m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 26, 2026

Fresh APVO Intelligence

Analysis is for subscribers only.

Aptevo Therapeutics announced that 10 of 47 (21%) evaluable frontline AML patients treated with mipletamig in combination with venetoclax and azacitidine advanced to allogeneic stem cell transplant, compared to a historical 0.7% rate with VEN+AZA alone in the VIALE-A trial. The company expects the…

Subscribe for Full Access